CA2392400A1 - Homologue humain normal de neoplasme cutane cd4+cd56+ - Google Patents

Homologue humain normal de neoplasme cutane cd4+cd56+ Download PDF

Info

Publication number
CA2392400A1
CA2392400A1 CA002392400A CA2392400A CA2392400A1 CA 2392400 A1 CA2392400 A1 CA 2392400A1 CA 002392400 A CA002392400 A CA 002392400A CA 2392400 A CA2392400 A CA 2392400A CA 2392400 A1 CA2392400 A1 CA 2392400A1
Authority
CA
Canada
Prior art keywords
cells
plasmacytoid
antibodies
monocytes
cutaneous neoplasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002392400A
Other languages
English (en)
Inventor
Laurent J. Galibert
Luis Borges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2392400A1 publication Critical patent/CA2392400A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouveaux monocytes plasmacytoïdes CD56?+¿ purifiés et isolés, l'homologue sain du néoplasme cutané CD4?+¿CD56?+¿ et leurs utilisations.
CA002392400A 1999-11-24 2000-11-21 Homologue humain normal de neoplasme cutane cd4+cd56+ Abandoned CA2392400A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16739499P 1999-11-24 1999-11-24
US60/167,394 1999-11-24
US17154699P 1999-12-22 1999-12-22
US60/171,546 1999-12-22
PCT/US2000/031968 WO2001038496A1 (fr) 1999-11-24 2000-11-21 Homologue humain normal de neoplasme cutane cd4?+cd56+¿

Publications (1)

Publication Number Publication Date
CA2392400A1 true CA2392400A1 (fr) 2001-05-31

Family

ID=26863130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002392400A Abandoned CA2392400A1 (fr) 1999-11-24 2000-11-21 Homologue humain normal de neoplasme cutane cd4+cd56+

Country Status (4)

Country Link
EP (1) EP1232246A1 (fr)
AU (1) AU1785601A (fr)
CA (1) CA2392400A1 (fr)
WO (1) WO2001038496A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire

Also Published As

Publication number Publication date
WO2001038496A1 (fr) 2001-05-31
EP1232246A1 (fr) 2002-08-21
AU1785601A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
JP7352473B2 (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
EP1255780B1 (fr) Methodes pour generer des anticorps monoclonaux humains
US6242579B1 (en) Antigen found on a small subset of human hematopoietic cells which binds to monoclonal antibody MG1
US7718376B2 (en) Identification and isolation of somatic stem cells and uses thereof
KR100868235B1 (ko) 수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포
KR20130036246A (ko) 사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍
AU678179B2 (en) Methods for positive immunoselection of stem cells
JPH07507202A (ja) ヒトｍｄｒ１マルチドラッグ耐性遺伝子産物に対するモノクローナル抗体およびその使用
EP0501233A1 (fr) Hybridomes et anticorps monoclonaux inhibant la prolifération de cellules T stimulées par l'anti-CD3
CN113784756A (zh) 生物结合分子
CA2353703A1 (fr) Anticorps monoclonaux humains specifiques de tumeurs et leur technique d'utilisation
CA3213163A1 (fr) Procedes et compositions pour dosages de puissance de coculture de lymphocytes t et utilisation avec des produits de therapie cellulaire
CA2392400A1 (fr) Homologue humain normal de neoplasme cutane cd4+cd56+
JP4563573B2 (ja) 抗原およびこの抗原を識別するモノクローナル抗体
AU1522395A (en) Monoclonal antibodies to antigens expressed by hematopoietic facilitatory cells
AU615233B2 (en) Monoclonal antibody that recognizes an epitope of the gamma chain of human t cell surface receptors
EP0325489B1 (fr) Leu 23: anticorps monoclonal pour monitoring d'activation de leucocytes
EP1261627A2 (fr) Anticorps diriges contre des cellules plasmatiques
Pesando et al. AFTR: a fifth human B-cell-specific surface antigen
JP3043629B2 (ja) 抗体１０３ｂ２
EP0931836A1 (fr) Peptide dérivé de l'interleukine-2 humaine pouvant accroítre la perméablilté vasculaire et les immunoconjugués en dérivant
JPH05503281A (ja) Ｈｔｌｖ−１ウイルス感染細胞の増殖阻害用組成物
Chapple Subpopulations of human bone marrow b cells: a phenotypic study
MXPA96002569A (en) Monoclonal antibodies to antigens expressed through hematopoyeti facilitatory cells
MXPA06000841A (es) Metodos y composiciones para aumentar la eficiencia de anticuerpos terapeuticos que utilizan compuestos para potenciar celulas nk

Legal Events

Date Code Title Description
FZDE Discontinued